I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
HCP

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Menorrhagia

Assessing and managing women with heavy menstrual bleeding

The definition of heavy menstrual bleeding (HMB) has changed – it is no longer solely defined by millilitres of blood loss per cycle but now includes the impact on a women’s physical, social and emotional quality of life.1

>80%

of women say that HMB affects their relationship with their partner or their performance at work, and it affects attendance at school or work for 68% of sufferers.2

As many as 1 in 3 women are expected to be negatively affected by HMB during their life but knowledge of the condition is poor.2,3 As such, many women are unaware that there are treatment options available for HMB2 – you can help her to speak up with three key questions:

See how these same three questions can help you to determine individualised treatment plans for your patients through these case studies

Case studies

  1. HELP Group. Heavy menstrual bleeding e-learning. Available at: https://uk.heavy-menstrual-bleeding.com/index.php?WT.mc_id=Mediconf_2018. Last accessed: October 2019.
  2. Bitzer J, et al. Open access Journal of Contraception, 2013;4:21–28.
  3. Hurskainen R, et al. Acta Obstetricia et Gynecologica 2007;86:749–757.

Once 'bothersome bleeding' has been identified, follow the HELP diagnostic pathway for HMB

diagnostic pathway for HMB

*You may wish to consider other treatments after trial of pharmaceutical options as per NICE guidelines: NICE Heavy Menstrual Bleeding NG88, 2018.

The HELP protocol has been adapted in the UK to reflect the 2018 updated NICE guidelines.

The HELP group is an expert panel of physicians from 12 countries with a special interest in heavy menstrual bleeding (HMB), supported by Bayer.

Download the interactive HELP treatment algorithm, including clinical considerations for all approved treatment options

Download

The HELP protocol has been adapted in the UK to reflect the 2018 updated NICE guidelines.
The HELP group is an expert panel of physicians from 12 countries with a special interest in heavy menstrual bleeding (HMB), supported by Bayer.

Bayer produces a number of materials to help women with HMB. Introduce your patients to HMB with 'myheavyperiods.co.uk'; a patient website with information on identifying HMB, the causes and treatment options.

Visit here

myheavyperiods.co.uk

NICE recommends Mirena® as a first-line pharmaceutical treatment for HMB with no identified pathology.1

MIrena levonorgestrel
  • Provides effective relief from idiopathic menorrhagia.2
  • Achieves menstrual blood loss reduction of up to 96%.3
  • Reduced bleeding promotes the increase of blood haemoglobin levels.2
  • Improves quality of life more than usual medical treatments (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone).4
  • Totally or occasionally absent menstruation has been associated with prolonged continuation with Mirena®.5
  • May effectively manage bleeding problems during the transition through menopause.6

  1. NICE clinical guidance NG88. Heavy menstrual bleeding: assessment and management, March 2018. Available at: https://www.nice.org.uk/guidance/ng88. Last accessed: June 2020.
  2. Bayer PLC. Mirena® Summary of Product Characteristics, 2020. 
  3. Stewart A, et al. Br J Obs Gyn 2001;108:74–86. 
  4. Gupta J, et al. N Engl J Med 2013;368:128–137.
  5. Backman T, et al. Br J Obs Gyn 2000;107:335–339. 
  6. Depypere H and Inki P. Climacteric 2015;18:1–13. 
Heavy Menstrual Bleeding (HMB): evidence-based learning for best practice.

A 30-minute, scientific e-learning course developed by the HELP expert panel of independent physicians*. Three case-based modules cover the diagnostic pathway and treatment algorithm for HMB to help you to counsel your patients effectively.

Start module

*The formation of the HELP expert panel and its ongoing work is supported by Bayer AG.

NICE clinical guideline NG88 covers the assessment and management of heavy menstrual bleeding. It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences. 

Download

NICE clinical guideline NG88

Gain real-world patient insights into heavy menstrual bleeding through these two short videos that can help both you and your patients relate to the condition. 

Sarah describes her experience of living with heavy menstrual bleeding since she was a teenager.

Wendy, 50 years old, explains the impact of heavy menstrual bleeding on her life before and after starting pharmaceutical treatment.

Recommendations

Bayer in women's health

Read more

Endometrial hyperplasia

Read more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0442 July 2020

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Tue, 08/25/2020 - 09:18

Bayer logo